Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016
CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer Source: International Congress 2019 – Lung cancer? Year: 2019
Alteration in clotting system in non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 74s Year: 2004
Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006
Does the lung function affect the survival time in patients with resected non-small cell lung cancer? Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007
Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017
Correlation between the activation of coagulation-fibrinolysis system and prognosis of nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 231s Year: 2001
A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Do cavitating non-small cell lung cancer patients have a more aggressive disease? Source: Eur Respir J 2006; 28: Suppl. 50, 84s Year: 2006
Non-small cell lung cancer resected molecular expression in COPD and low function pulmonary patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014
Surgical treatment of nonsmall cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=170 Year: 2001
Outcome of treated advanced non-small cell lung cancer associated with central airway obstruction Source: Eur Respir J 2006; 28: Suppl. 50, 796s Year: 2006
Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004